GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » Net Income (Continuing Operations)

Antengene (FRA:722) Net Income (Continuing Operations) : €-41.36 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Antengene Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Antengene's Net Income (Continuing Operations) for the six months ended in Jun. 2024 was €-21.39 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2024 was €-41.36 Mil.

Antengene Net Income (Continuing Operations) Historical Data

The historical data trend for Antengene's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Net Income (Continuing Operations) Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
Get a 7-Day Free Trial -368.17 -91.08 -81.44 -74.64 -41.88

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.89 -28.19 -46.55 -21.39 -19.97

Antengene Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-41.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene  (FRA:722) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Antengene Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Antengene's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » Net Income (Continuing Operations)
Comparable Companies
HKSE:01521 HKSE:02509 HKSE:02487 HKSE:02181 HKSE:06978 HKSE:02563 HKSE:02566 HKSE:03681 HKSE:02511 HKSE:06998 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
06996:Hong Kong
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Website
https://www.antengene.com
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Antengene Headlines

No Headlines